We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
Read MoreHide Full Article
Key Takeaways
Ionis posted a smaller-than-expected Q3 loss and a 17% year-over-year revenue increase.
Commercial revenue jumped 53% YoY on strong Tryngolza sales and higher Wainua royalties.
The company raised its 2025 revenue outlook to $875-$900 million, citing solid drug uptake.
Ionis Pharmaceuticals (IONS - Free Report) reported third-quarter 2025 adjusted loss per share of 61 cents, much narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company reported an adjusted loss of 72 cents.
The adjusted earnings exclude compensation expenses related to equity awards. Including this special item, loss stood at 80 cents per share compared to a loss of 95 cents in the year-ago period.
Total revenues were $157 million, which also beat the Zacks Consensus Estimate of about $130 million. The reported figure rose 17% over the year-ago period.
IONS Stock Performance
Year to date, shares of Ionis have soared 106% compared with the industry’s 8% growth.
Image Source: Zacks Investment Research
Ionis’ Diverse Revenue Stream
Ionis licensed Spinraza to Biogen (BIIB - Free Report) , which is responsible for commercializing the drug. Spinraza is approved for treating spinal muscular atrophy worldwide. Ionis receives royalties from Biogen on Spinraza’s sales. It also earns royalties from Biogen’s sales of Qalsody, approved for treating amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. Qalsody was launched in the United States in 2023 and in the EU in May 2024.
Ionis and AstraZeneca’s (AZN - Free Report) Wainua (or Wainzua in Europe) was approved by the FDA in 2023 for treating patients with hereditary transthyretin-mediated amyloid polyneuropathy, commonly called hATTR-PN or ATTRv-PN. While both companies co-market Wainua for ATTRv-PN in the country, AZN holds exclusive rights to commercialize the drug in ex-U.S. markets.
The company has two wholly-owned marketed medications — Tryngolza for familial chylomicronemia syndrome (FCS) and Dawnzera for hereditary angioedema (HAE). While Tryngolza was approved and launched in December 2024, Dawnzera was approved in August. Both drugs are Ionis’ first independent product launches. To market these drugs across ex-U.S. territories, the company has partnered with Sobi (for Tryngolza) and Otsuka (for Dawnzera).
IONS' Commercial Revenues Rise
Commercial revenues, which include sales of wholly owned drugs and royalties on partnered drugs, surged 53% year over year to $116 million during the quarter. This growth was primarily driven by Tryngolza product sales and Wainua royalties. The metric surpassed the Zacks Consensus Estimate of $101 million.
Notably, this was the third full quarter in which Ionis recognized product sales for Tryngolza. This drug added $32 million to the company’s top line compared with $19 million in the previous quarter, driven by a robust launch momentum.
Spinraza royalties totaled $56 million, down 2% year over year. Per Ionis, Spinraza sales during the quarter stood at $374 million, suggesting a decline of 2% over the year-ago period.
Wainua royalty revenues amounted to $13 million compared with $10 million in the previous quarter. This drug generated sales of $59 million, as recorded by AstraZeneca. The EU launch for the drug is currently underway.
Ionis recorded $7 million as other royalties, up 40% year over year. This metric also includes royalties from Qalsody product sales.
IONS' R&D Revenues Decline
Though R&D revenues fell 29% year over year to $41 million, the figure still beat the Zacks Consensus Estimate of $25 million.
Collaborative agreement revenues totaled $31 million compared with $45 million in the year-ago quarter. Joint development revenues for Wainua from partner AstraZeneca amounted to $10 million, down 23% year over year.
IONS' Costs Rise
Adjusted operating costs rose 14% year over year to $286 million in the quarter. While SG&A costs increased 71% to support commercialization efforts for Wainua, Tryngolza and Dawnzera, R&D costs declined 1% as several late-stage studies ended.
IONS Raises 2025 Guidance
The latest guidance marks the third upward revision to Ionis’ 2025 financial outlook. The company now expects total revenues to be between $875 million and $900 million, up from the prior guidance of $825-$850 million. The Zacks Consensus Estimate is pegged at nearly $858 million.
Per Ionis, the revised guidance reflects the encouraging uptake for Tryngolza. The company also raised the guidance for the drug’s sales for the full year, now expecting the same to be between $85 million and $95 million (previously: $75-$80 million).
The adjusted operating loss is now expected to be between $275 million and $300 million, down from the previous guidance of $300-$325 million.
Ionis now expects to end the year with over $2.1 billion in cash (previously: about $2.0 billion).
Updates on IONS’ Wholly-Owned Pipeline
Last month, Ionis reported positive results from two phase III studies — CORE and CORE2 — which evaluated Tryngolza for severe hypertriglyceridemia, which involves a much larger patient population. Both studies met their primary endpoint, with Tryngolza-treated participants showing a statistically significant, placebo-adjusted reduction in triglyceride (TG) levels. The studies also showed a significant reduction in acute pancreatitis (AP) events — a key secondary endpoint.
Earlier in May, Ionis reported that the late-stage ESSENCE study, which evaluated Tryngolza in people with moderate hypertriglyceridemia (marked by TG levels ≥150 mg/dL), also met its primary goal. Based on data from the ESSENCE, CORE and CORE2 studies, Ionis plans to submit an FDA filing for Tryngolza’s label expansion before the end of 2025. Like FCS, Ionis also has a first-mover advantage in the sHTG indication.
Some other important wholly-owned candidates in Ionis’ pipeline include zilganersen and ION582. Last month, the company reported that a late-stage study evaluating zilganersen for a rare neurological condition called Alexander’s disease (AxD) met its primary endpoint. Based on these results, a regulatory filing is planned with the FDA next year in Q1.
Ionis recently started the phase III REVEAL study evaluating ION582 for treating a rare and serious neurodevelopmental disorder called Angelman syndrome.
Updates on IONS’ Partnered Drugs
AstraZeneca and Ionis are also developing Wainua for another form of amyloidosis called cardiomyopathy caused by hereditary TTR amyloidosis (ATTR-CM), which has a larger market than ATTRv-PN. Data from the phase III CARDIO-TTRANSform study in ATTR-CM is expected in the second half of 2026.
Among some wholly-owned candidates, Ionis’ partner Novartis (NVS - Free Report) is developing pelacarsen in late-stage studies for elevated Lp(a)-driven CVD. Along with GSK, the company is developing bepirovirsen as a potential treatment for patients with chronic hepatitis B virus in two ongoing late-stage studies. Data on both these partnered programs is expected in the first half of 2026.
Image: Bigstock
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
Key Takeaways
Ionis Pharmaceuticals (IONS - Free Report) reported third-quarter 2025 adjusted loss per share of 61 cents, much narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company reported an adjusted loss of 72 cents.
The adjusted earnings exclude compensation expenses related to equity awards. Including this special item, loss stood at 80 cents per share compared to a loss of 95 cents in the year-ago period.
Total revenues were $157 million, which also beat the Zacks Consensus Estimate of about $130 million. The reported figure rose 17% over the year-ago period.
IONS Stock Performance
Year to date, shares of Ionis have soared 106% compared with the industry’s 8% growth.
Image Source: Zacks Investment Research
Ionis’ Diverse Revenue Stream
Ionis licensed Spinraza to Biogen (BIIB - Free Report) , which is responsible for commercializing the drug. Spinraza is approved for treating spinal muscular atrophy worldwide. Ionis receives royalties from Biogen on Spinraza’s sales. It also earns royalties from Biogen’s sales of Qalsody, approved for treating amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. Qalsody was launched in the United States in 2023 and in the EU in May 2024.
Ionis and AstraZeneca’s (AZN - Free Report) Wainua (or Wainzua in Europe) was approved by the FDA in 2023 for treating patients with hereditary transthyretin-mediated amyloid polyneuropathy, commonly called hATTR-PN or ATTRv-PN. While both companies co-market Wainua for ATTRv-PN in the country, AZN holds exclusive rights to commercialize the drug in ex-U.S. markets.
The company has two wholly-owned marketed medications — Tryngolza for familial chylomicronemia syndrome (FCS) and Dawnzera for hereditary angioedema (HAE). While Tryngolza was approved and launched in December 2024, Dawnzera was approved in August. Both drugs are Ionis’ first independent product launches. To market these drugs across ex-U.S. territories, the company has partnered with Sobi (for Tryngolza) and Otsuka (for Dawnzera).
IONS' Commercial Revenues Rise
Commercial revenues, which include sales of wholly owned drugs and royalties on partnered drugs, surged 53% year over year to $116 million during the quarter. This growth was primarily driven by Tryngolza product sales and Wainua royalties. The metric surpassed the Zacks Consensus Estimate of $101 million.
Notably, this was the third full quarter in which Ionis recognized product sales for Tryngolza. This drug added $32 million to the company’s top line compared with $19 million in the previous quarter, driven by a robust launch momentum.
Spinraza royalties totaled $56 million, down 2% year over year. Per Ionis, Spinraza sales during the quarter stood at $374 million, suggesting a decline of 2% over the year-ago period.
Wainua royalty revenues amounted to $13 million compared with $10 million in the previous quarter. This drug generated sales of $59 million, as recorded by AstraZeneca. The EU launch for the drug is currently underway.
Ionis recorded $7 million as other royalties, up 40% year over year. This metric also includes royalties from Qalsody product sales.
IONS' R&D Revenues Decline
Though R&D revenues fell 29% year over year to $41 million, the figure still beat the Zacks Consensus Estimate of $25 million.
Collaborative agreement revenues totaled $31 million compared with $45 million in the year-ago quarter. Joint development revenues for Wainua from partner AstraZeneca amounted to $10 million, down 23% year over year.
IONS' Costs Rise
Adjusted operating costs rose 14% year over year to $286 million in the quarter. While SG&A costs increased 71% to support commercialization efforts for Wainua, Tryngolza and Dawnzera, R&D costs declined 1% as several late-stage studies ended.
IONS Raises 2025 Guidance
The latest guidance marks the third upward revision to Ionis’ 2025 financial outlook. The company now expects total revenues to be between $875 million and $900 million, up from the prior guidance of $825-$850 million. The Zacks Consensus Estimate is pegged at nearly $858 million.
Per Ionis, the revised guidance reflects the encouraging uptake for Tryngolza. The company also raised the guidance for the drug’s sales for the full year, now expecting the same to be between $85 million and $95 million (previously: $75-$80 million).
The adjusted operating loss is now expected to be between $275 million and $300 million, down from the previous guidance of $300-$325 million.
Ionis now expects to end the year with over $2.1 billion in cash (previously: about $2.0 billion).
Updates on IONS’ Wholly-Owned Pipeline
Last month, Ionis reported positive results from two phase III studies — CORE and CORE2 — which evaluated Tryngolza for severe hypertriglyceridemia, which involves a much larger patient population. Both studies met their primary endpoint, with Tryngolza-treated participants showing a statistically significant, placebo-adjusted reduction in triglyceride (TG) levels. The studies also showed a significant reduction in acute pancreatitis (AP) events — a key secondary endpoint.
Earlier in May, Ionis reported that the late-stage ESSENCE study, which evaluated Tryngolza in people with moderate hypertriglyceridemia (marked by TG levels ≥150 mg/dL), also met its primary goal. Based on data from the ESSENCE, CORE and CORE2 studies, Ionis plans to submit an FDA filing for Tryngolza’s label expansion before the end of 2025. Like FCS, Ionis also has a first-mover advantage in the sHTG indication.
Some other important wholly-owned candidates in Ionis’ pipeline include zilganersen and ION582. Last month, the company reported that a late-stage study evaluating zilganersen for a rare neurological condition called Alexander’s disease (AxD) met its primary endpoint. Based on these results, a regulatory filing is planned with the FDA next year in Q1.
Ionis recently started the phase III REVEAL study evaluating ION582 for treating a rare and serious neurodevelopmental disorder called Angelman syndrome.
Updates on IONS’ Partnered Drugs
AstraZeneca and Ionis are also developing Wainua for another form of amyloidosis called cardiomyopathy caused by hereditary TTR amyloidosis (ATTR-CM), which has a larger market than ATTRv-PN. Data from the phase III CARDIO-TTRANSform study in ATTR-CM is expected in the second half of 2026.
Among some wholly-owned candidates, Ionis’ partner Novartis (NVS - Free Report) is developing pelacarsen in late-stage studies for elevated Lp(a)-driven CVD. Along with GSK, the company is developing bepirovirsen as a potential treatment for patients with chronic hepatitis B virus in two ongoing late-stage studies. Data on both these partnered programs is expected in the first half of 2026.
Ionis Pharmaceuticals, Inc. Price
Ionis Pharmaceuticals, Inc. price | Ionis Pharmaceuticals, Inc. Quote
IONS’ Zacks Rank
Ionis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.